Randolph Building 401 Dulany Street Customer Service Window CLIENT REF. NO. E-297-2002/0-US-02 Mail Stop PCT Alexandria, VA 22314 TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 USC 371 AND 37 CFR 1.491 INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO. PCT/US2002/033243 15 October 2002 (15.10.2002) TITLE OF INVENTION METHODS OF PREPARING LYMPHOCYTES THAT EXPRESS INTERLEUKIN-2 AND THEIR USE IN THE TREATMENT OF CANCER APPLICANT(S) FOR DO/EO/US Liu et al.. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 USC 371 and 37 CFR 1.491. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 USC 371 and 37 CFR 1.491. This is an express request to begin national examination procedures (35 USC 371(f)). 3. The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). A copy of the International Application as filed (35 USC 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 USC 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 USC 371(c)(3)). An oath or declaration of the inventor(s) (35 USC 371(c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 USC 371(c)(5)). 11. Nucleotide and/or Amino Acid Sequence Submission Specification Sequence Listing on: CD-ROM or CD-R (2 copies); or Paper Copy Statement verifying identity of above copies Items 12 to 19 below concern other document(s) or information included: 12. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. □ Form PTO-1449 Copies of References (except for U.S. patents and applications) 13. An assignment for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 15. A substitute specification. 16. A change of power of attorney and/or address letter. 17. Application Data Sheet Under 37 CFR 1.76 18. Return Receipt Postcard

19. Other items or information: Copy of PCT/US2002/033243 International Search Report

JC12 Rec'd PCT/PTC 1 2 APR 2005

U.S. APPLICATION NO. INTERNATIONAL APPLICATION NO. ATTORNEY DOCKET NO.						CLIENT REF. N	
Unassigle () / 5 3 1 PC/(U) 2002/033243 234872						E-297-2002/	
20. The following fees are submitted:						CALCULATIONS	PTO USE ONLY
National Stage Filing Fee						\$300.00	
Search Fee		\$100.00					
USPTO was ISA \$100.00  Search report provided to USPTO by other entity \$400.00							
<del>                                    </del>							
All other situations \$500.00  Examination Fee						\$100.00	
US was IPEA and all claims satisfy PCT Article 33(1)-(4) \$100.00						\$100.00	
All other situ							
All other situ	ations	\$500.00					
☐ Claim Fee		<b>35</b> 0.00					
CLAIMS	-T	NUMBER FILED	NUMBER E	EXTRA	RATE		
Total Claims	-	32 -20=	NOMBERT	12	x \$ 50.00	\$600.00	
Independent Clair		2 - 3 =		0	x \$200.00	\$0.00	
		it Claim(s) (if applicable)	<u> </u>		+\$360.00	\$	
		\$ \$					
Application Size Fee (\$250 for each additional 50 sheets over 100)  Surcharge of \$130.00 for furnishing the National fee or oath or declaration							
later than 20 30 months from the earliest claimed priority date.						\$ \$	
iater than 20 30 months from the earnest channed priority date.						Ψ	
TOTAL OF ABOVE CALCULATIONS=						\$1,100.00	
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are						\$1,100.00	
reduced by 1/2.						<b>\$</b> ( )	
1cddccd by 17	<u> </u>					*	
SUBTOTAL=						\$1,100.00	
Processing fe	e of \$1	30.00 for furnishing English	Translation la	ter than [			
months from the earliest claimed priority date.						\$	
TOTAL NATIONAL FEE=						\$1,100.00	
Fee for recording the enclosed assignment. The assignment must be accompanied by an							
appropriate cover	sheet.	\$					
		\$1,100.00					
					•	Amount to be:	
,						refunded	\$
						charged:	\$
		•	•				
a. No fee is	believ	•					
N							
b. Please charge Deposit Account No. 12-1216 the total fee indicated above.							
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to							
Deposit Account No. 12-1216. A duplicate copy of this sheet is enclosed.							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR							
1.137(a) or (b)) must be filed and granted to restore the application to pending status.							
/ //							
				V	. (/. <b>!</b> //		
SEND ALL COR	RESPO						
45733:		o. 39,799					
1		4900					
Chicago, Illinois 60601-6780						)	
(312) 616-5600 (telephone)							
(312) 616-5700 (facsimile)							

10/531145

## CERTIFICATION UNDER 37 CFR 4112 Rec'd PCT/PTC 1 2 APR 2005

"Express Mail" Label Number:

EV420387205US

Date of Deposit:

April 12, 2005

I hereby certify that this transmittal document with respect to the U.S. national phase of the above-referenced International Patent Application, including all of the items listed thereon as enclosures, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

XAVIER PILLA

Page 3 of 3

NIH Patent National Phase Transmittal (Revised 2/15/05)